These findings suggest that CKS1B may serve as a prognostic marker in pancreatic cancer and a potential therapeutic target for overcoming drug resistance, offering new opportunities to improve patient survival through combination chemotherapy. This evidence concerns the gene CKS1B and pancreatic neoplasm.